<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641340</url>
  </required_header>
  <id_info>
    <org_study_id>INS002-15-050</org_study_id>
    <nct_id>NCT02641340</nct_id>
  </id_info>
  <brief_title>Fentanyl Sublingual Spray in Opioid Naive Participants</brief_title>
  <official_title>A Phase 1, Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fentanyl Sublingual Spray in Opioid Naive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INSYS Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to determine the pharmacokinetic and pharmacodynamic
      relationship of multiple dose administration of fentanyl sublingual spray in opioid naive
      participants. The secondary objective is to determine the safety and tolerability of multiple
      dose administration of fentanyl sublingual spray in opioid naive subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For all cycles, blood will be drawn according to the following schedule:

      The 0 time (pre-dose) blood sample will be collected within 60 minutes prior to first study
      drug administration.

      Cohort l: 0 (pre-dose), 5, 15 and 30 minutes after the first dose and at 1, 2, 4 (prior to
      second-dose), 4.083, 4.25, 4.5, 5, 6, 8 (prior to third-dose), 8.083, 8.25, 8.5, 9, 10, 12,
      16 and 24 hours after the first dose.

      Cohort 2: 0 (pre-dose), 5, 15 and 30 minutes after the first dose and at 1, 2 (prior to
      second-dose), 2.083, 2.25, 2.5, 3, 4 (prior to third-dose), 4.083, 4.25, 4.5, 5, 6, 8, 10,
      12, 16 and 24 hours after the first dose.

      Cohort 3: 0 (pre-dose), 5, 15, 30 and 45 minutes after the first dose and at 1 (prior to
      second-dose), 1.083, 1.25, l.5, 1.75, 2 (prior to third-dose), 2.083, 2.25, 2.5, 2.75, 3, 4,
      8, 12, 16 and 24 hours after the first dose.

      Cohort 4: 0 (pre-dose), 5, 15, 30 (prior to the second-dose), 35, and 45 minutes after the
      first dose and at I (prior to the third-dose), 1.083, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3,
      4, 8, 12, 16 and 24 hours after the first dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>within 24 hours (see detailed description)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach peak or maximum concentration following drug administration (Tmax)</measure>
    <time_frame>within 24 hours (see detailed description)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve</measure>
    <time_frame>within 24 hours (see detailed description)</time_frame>
    <description>Categories: during a dosing interval (AUCtau ), from the time of dosing to infinity (AUC0-inf), from the time of dosing to the last quantifiable time point (AUC0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent elimination rate constant in the terminal phase by non-compartmental analysis</measure>
    <time_frame>within 24 hours (see detailed description)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Corresponding half-life (t1/2)</measure>
    <time_frame>within 24 hours (see detailed description)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough concentration during multiple dosing prior to next dose (Ctrough)</measure>
    <time_frame>within 24 hours (see detailed description)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratios</measure>
    <time_frame>within 24 hours (see detailed description)</time_frame>
    <description>Categories: of Cmax (ARcmax), based on trough concentration (ARctrough), of AUCtau (ARauctau)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose normalized Cmax</measure>
    <time_frame>within 24 hours (see detailed description)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose normalized AUC</measure>
    <time_frame>within 24 hours (see detailed description)</time_frame>
    <description>Categories: AUC0-1, AUC0-inf, AUCtau</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants with respiratory depression requiring the use of naloxone</measure>
    <time_frame>within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with hypoxia requiring oxygen administration</measure>
    <time_frame>within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants needing noninvasive respiratory maneuvers (e.g., jaw thrust, bag-valve mask) to improve respiratory status at any point during the study</measure>
    <time_frame>within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with hypotension requiring intervention</measure>
    <time_frame>within 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Pharmacology</condition>
  <arm_group>
    <arm_group_label>Cycle 1, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fentanyl Sublingual Spray (FSS) low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 1, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 1, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 1, Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 2, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 2, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 2, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 2, Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 3, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 3, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 3, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 3, Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl Sublingual Spray</intervention_name>
    <description>Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)</description>
    <arm_group_label>Cycle 1, Cohort 1</arm_group_label>
    <arm_group_label>Cycle 1, Cohort 2</arm_group_label>
    <arm_group_label>Cycle 1, Cohort 3</arm_group_label>
    <arm_group_label>Cycle 1, Cohort 4</arm_group_label>
    <arm_group_label>Cycle 2, Cohort 1</arm_group_label>
    <arm_group_label>Cycle 2, Cohort 2</arm_group_label>
    <arm_group_label>Cycle 2, Cohort 3</arm_group_label>
    <arm_group_label>Cycle 2, Cohort 4</arm_group_label>
    <arm_group_label>Cycle 3, Cohort 1</arm_group_label>
    <arm_group_label>Cycle 3, Cohort 2</arm_group_label>
    <arm_group_label>Cycle 3, Cohort 3</arm_group_label>
    <arm_group_label>Cycle 3, Cohort 4</arm_group_label>
    <other_name>SUBSYS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl Citrate IV</intervention_name>
    <description>Fentanyl Citrate 50 mcg, delivered intravenously</description>
    <arm_group_label>Cycle 1, Cohort 1</arm_group_label>
    <arm_group_label>Cycle 1, Cohort 2</arm_group_label>
    <arm_group_label>Cycle 1, Cohort 3</arm_group_label>
    <arm_group_label>Cycle 1, Cohort 4</arm_group_label>
    <arm_group_label>Cycle 2, Cohort 1</arm_group_label>
    <arm_group_label>Cycle 2, Cohort 2</arm_group_label>
    <arm_group_label>Cycle 2, Cohort 3</arm_group_label>
    <arm_group_label>Cycle 2, Cohort 4</arm_group_label>
    <arm_group_label>Cycle 3, Cohort 1</arm_group_label>
    <arm_group_label>Cycle 3, Cohort 2</arm_group_label>
    <arm_group_label>Cycle 3, Cohort 3</arm_group_label>
    <arm_group_label>Cycle 3, Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification and contraception

          -  Willing and able to remain confined in the study unit for the entire duration of each
             treatment period and comply with restrictions related food, drink and medications

          -  Voluntarily consents to participate and provides written informed consent prior to any
             protocol-specific procedures

        Exclusion Criteria:

          -  History or current use of over-the-counter medications, dietary supplements, or drugs
             (including nicotine and alcohol) outside protocol-specified parameters

          -  Signs, symptoms or history of any condition that, per protocol or in the opinion of
             the investigator, might compromise:

               1. the safety or well-being of the participant or study staff

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding)

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neha Parikh</last_name>
    <role>Study Director</role>
    <affiliation>INSYS Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Clinical Research, Inc.</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

